A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
about
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Overview of the clinical efficacy of investigational anticancer drugs.Farnesyl transferase inhibitors in the treatment of breast cancer.Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.Therapeutic silencing of KRAS using systemically delivered siRNAs.Lonafarnib in cancer therapy.Biological agents versus chemotherapy in the treatment of colorectal cancer.Genetics of melanomaFarnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasThe new paradigm in the treatment of colorectal cancer: are we hitting the right target?Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastomaLonafarnib for cancer and progeria.New target agents in the treatment of colorectal cancer patients.Recent advances in oral anticancer agents for colon cancer.In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus.The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.Working together: Farnesyl transferase inhibitors and statins block protein prenylation.Molecular and clinical aspects of hepatitis D virus infections.RhoB: Team Oncogene or Team Tumor Suppressor?
P2860
Q27853172-12BED613-DE7D-48A0-BFF7-626FD763EDB0Q33644407-841B74F1-6047-492D-93E6-677E3B6E959EQ33914284-70CEEB7C-B9B4-4542-8258-5F539F0322D5Q34651253-E4C4C7D1-3B44-4D96-8009-91F69F3F9465Q34659415-0E03940D-88F3-4691-B03C-0918632BD687Q35067125-20050225-D781-4D84-8A14-8F048D3CF906Q35073354-5F8AF771-D0D9-49BB-B7B0-F7C310EC3EA5Q35383553-62A8043D-A20E-45F8-94AA-684F09D930DDQ35525553-0D8C3BF5-81B4-4B25-BD3B-8CE8EC20B796Q35559932-2636836D-C700-471D-9D9B-4D8CC397A87BQ36491847-D5E7F2C6-B897-4844-959B-944616EA69D0Q36521850-7F256B0C-BD6E-4151-9B27-057FD55084A8Q36563659-FAE4B29A-0DA3-4E50-A62D-0D0820879F7EQ36693797-35468EE6-7A71-4DFE-BE5A-C15AF7DAA59BQ36736346-87E65B01-26FF-4281-B2D1-F1D5831CCF90Q37727000-E971B107-FE50-4265-AA99-9F1FDA811814Q38012480-06E9CDB0-7C65-4269-BFB5-8B68AD2178E5Q38089157-D241392F-A3A1-4FFB-A7EC-45401E41BA94Q38167885-172D75F1-7E29-49AA-858E-7213E1AB1D73Q39793276-F04E8133-5A31-4EBF-A9BD-5A6538D4DC68Q40134426-9DBCC64E-FB99-45F7-BB53-E833D8CB7FEAQ40149906-9C2B199D-AC30-4815-A657-FA7E219C8ECAQ42969554-518CD689-6C24-4FC3-9925-0C89DAF3658EQ49550467-31375A5C-748C-41CD-B994-CB426E22F612
P2860
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@ast
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@en
type
label
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@ast
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@en
prefLabel
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@ast
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@en
P2093
P2860
P356
P1433
P1476
A phase II trial of farnesyl p ...... 5-fluorouracil and irinotecan.
@en
P2093
D P Kelsen
E Hollywood
E O'Reilly
P Statkevich
P2860
P304
P356
10.1093/ANNONC/MDF173
P577
2002-07-01T00:00:00Z